Merck & Co.’s cancer drug Keytruda helped extend survival and prevented disease progression when tested in a late-stage study in combination with chemotherapy for a type of lung cancer.
Deal activity is rampant as Big Pharma gobbles up next-generation medicines and technologies to help overcome maturing pipelines and biosimilar threats.
For the pharmaceutical industry, 2016 brought new blockbusters onto the market to ease the pain of patent expirations.
Shares of newly dubbed Sesen Bio plunged 23 percent after the company released positive, three-month data from its ongoing Phase III high-grade non-muscle invasive bladder cancer trial.
Nabriva Therapeutics Plc’s potential new antibiotic to treat a common form of pneumonia met the main goal of a key clinical trial.
Roche’s recently launched medicine Hemlibra dramatically reduced bleeding in a broad population of hemophilia patients, results from two clinical trials showed.
Johnson & Johnson’s Janssen division decided to end clinical trials of atabacestat, a BACE inhibitor, for Alzheimer’s disease.
Genentech, a Roche company, released follow-up data from its Phase III ALEX trial comparing its Alecensa (alectinib) to Pfizer’s Xalkori (crizotinib) in late-stage non-small cell lung cancer.
AstraZeneca’s first respiratory biologic medicine Fasenra failed to meet its target in a clinical trial treating patients with moderate to very severe chronic obstructive pulmonary disease (COPD).
As Boston-based Rhythm Pharmaceuticals moves its lead obesity treatment into a second Phase III trial, the company was bolstered by the publication of longer-term data from its Phase II study of setmelanotide in Nature Medicine.
Roche’s hopes of Tecentriq catching rival medicines from Merck and Bristol-Myers Squibb were dealt a blow after the immunotherapy failed a key combination trial.
Janssen Pharmaceuticals is eying a potential breakthrough in treating refractory major depressive disorder.
Celgene is eying the first quarter of 2019 to submit a second New Drug Application (NDA) for the multiple sclerosis treatment ozanimod.
British scientists have developed a far more accurate blood test to diagnose peanut allergy, offering a better way to monitor a significant food hazard.
A Finnish study suggests a regular sauna habit is associated with a lower risk of strokes.
Bristol-Myers dropped two Phase III clinical trials of the IDO1 inhibitor acquired from Flexus Biosciences.
Allergan Plc announced positive results from a second Phase III trial for a 50-milligram dose of the company’s drug for acute migraine, reproducing results from the previous clinical study.
International scientists identified 44 genetic variants that can increase the risk of developing major depression and found that all humans carry at least some of them.
Boehringer Ingelheim presented the family-owned pharmaceutical company’s latest pipeline updates at an R&D press conference entitled ‘Transcending Disease Boundaries’ at its global headquarters in Ingelheim, Germany.
The concept of combining two immunotherapy drugs to fight lung cancer suffered a fresh blow from the failure of an AstraZeneca clinical study.
An arthritis drug developed by Eli Lilly and Co. and Incyte Corp. should not be approved at a 4-milligram dose, advisers to the U.S. FDA voted.
Bluebird bio announced interim data from two different two-year clinical trials of LentiGlobin gene therapy for transfusion-dependent beta-thalassemia (TDT).